$IMG
Stock $img

$img Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224002501 Filed on January 16, 2024

Income Statement

Concept	2024 Q1	2023 Q3	2023
Revenue	$605.8K	$782.7K	$3.349M
YoY Change	-22.45%	30.27%	7.71%
Cost Of Revenue	$752.0K	$938.2K	$3.340M
YoY Change	1.0%	45.7%	3.74%
Gross Profit	-$146.2K	-$155.5K	$8.818K
YoY Change	-499.21%	260.71%	-107.99%
Gross Profit Margin	-24.14%	-19.87%	0.26%
Selling, General & Admin	$86.64K	$116.6K	$263.9K
YoY Change	126.98%		-97.51%
% of Gross Profit			2992.52%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$68.21K	$40.65K	$220.7K
YoY Change	75.66%	-51.77%	-41.85%
% of Gross Profit			2502.3%
Operating Expenses	$1.465M	$2.552M	$8.880M
YoY Change	-26.14%	23.74%	-21.36%
Operating Profit	-$1.611M	-$2.708M	-$8.872M
YoY Change	-17.24%	28.59%	-22.2%
Interest Expense	-$550.00	-$2.380K	$8.040K
YoY Change	-110.28%	164.44%	27.13%
% of Operating Profit
Other Income/Expense, Net	-$42.63K	$137.2K	$251.7K
YoY Change	58.36%	-138.75%	-56.21%
Pretax Income	-$1.654M	-$2.573M	-$8.749M
YoY Change	-15.95%	-17.95%	-25.84%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.654M	-$2.573M	-$8.749M
YoY Change	-15.95%	-17.95%	-25.84%
Net Earnings / Revenue	-273.03%	-328.74%	-261.27%
Basic Earnings Per Share	-$1.28		-$11.95
Diluted Earnings Per Share	-$1.28	-$3.30	-$11.95
COMMON SHARES
Basic Shares Outstanding	1.282M shares	776.7K shares	732.4K shares
Diluted Shares Outstanding	1.295M shares		732.4K shares

Balance Sheet

Concept	2024 Q1	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$0.00	$1.373M	$1.373M
YoY Change	-100.0%	-83.49%	-83.49%
Cash & Equivalents		$1.373M
Short-Term Investments
Other Short-Term Assets	$382.8K	$418.2K	$418.2K
YoY Change	27.03%	-23.65%	-23.65%
Inventory	$1.208M	$998.1K	$998.1K
Prepaid Expenses
Receivables	$397.6K	$586.9K	$586.9K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.989M	$3.376M	$3.376M
YoY Change	-70.1%	-66.76%	-66.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$522.6K	$309.6K	$712.8K
YoY Change	29.73%	-41.05%	-38.96%
Goodwill
YoY Change
Intangibles	$95.00K	$110.0K
YoY Change	-24.0%	-21.43%
Long-Term Investments	$160.1K	$162.3K	$162.3K
YoY Change	-3.61%	-4.34%	-4.34%
Other Assets	$72.91K	$79.68K	$79.68K
YoY Change	-16.41%	2.2%	2.21%
Total Long-Term Assets	$1.228M	$1.065M	$1.065M
YoY Change	-5.55%	-31.54%	-31.54%
TOTAL ASSETS
Total Short-Term Assets	$1.989M	$3.376M	$3.376M
Total Long-Term Assets	$1.228M	$1.065M	$1.065M
Total Assets	$3.217M	$4.441M	$4.441M
YoY Change	-59.55%	-62.08%	-62.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.613M	$1.904M	$1.904M
YoY Change	1143.24%	1574.39%	1574.36%
Accrued Expenses	$295.5K	$216.1K	$216.1K
YoY Change	-60.94%	-69.41%	-80.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$291.5K	$30.80K	$30.80K
YoY Change	658.92%	-5.14%	-5.14%
Total Short-Term Liabilities	$3.534M	$2.556M	$2.556M
YoY Change	98.81%	59.78%	59.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$256.3K	$47.94K	$210.2K
YoY Change	215.93%	-27.9%	-37.1%
Total Long-Term Liabilities	$257.4K	$210.2K	$210.2K
YoY Change	11.56%	-42.97%	-42.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.534M	$2.556M	$2.556M
Total Long-Term Liabilities	$257.4K	$210.2K	$210.2K
Total Liabilities	$3.792M	$2.767M	$2.767M
YoY Change	88.78%	40.54%	40.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$77.17M	-$73.37M
YoY Change	12.22%	13.54%
Common Stock	$76.43M	$74.93M
YoY Change	2.5%	0.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$574.9K	$1.674M	$1.674M
YoY Change
Total Liabilities & Shareholders Equity	$3.217M	$4.441M	$4.441M
YoY Change	-59.55%	-62.08%	-62.08%

Cashflow Statement

Concept	2024 Q1	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$1.654M	-$2.573M	-$8.749M
YoY Change	-15.95%	-17.95%	-25.84%
Depreciation, Depletion And Amortization	$68.21K	$40.65K	$220.7K
YoY Change	75.66%	-51.77%	-41.85%
Cash From Operating Activities	-$661.0K	-$1.896M	-$6.926M
YoY Change	-61.94%	6.24%	-7.18%
INVESTING ACTIVITIES
Capital Expenditures	-$800.00	-$13.76K	$16.24K
YoY Change		-160.48%	-91.53%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$800.00	$13.76K	-$16.24K
YoY Change		-39.54%	-97.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	219.9K	-6.030K	-$36.03K
YoY Change	-1831.73%	-100.23%	-100.63%
NET CHANGE
Cash From Operating Activities	-661.0K	-1.896M	-$6.926M
Cash From Investing Activities	800.0	13.76K	-$16.24K
Cash From Financing Activities	219.9K	-6.030K	-$36.03K
Net Change In Cash	-440.3K	-1.889M	-$6.942M
YoY Change	-74.83%	-313.09%	177.58%
FREE CASH FLOW
Cash From Operating Activities	-$661.0K	-$1.896M	-$6.926M
Capital Expenditures	-$800.00	-$13.76K	$16.24K
Free Cash Flow	-$660.2K	-$1.883M	-$6.943M
YoY Change	-61.99%	4.15%	-9.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001527613
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2023	NUZE	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment		usd
CY2023	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost		usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	NUZE	Proceeds From Issuance Of Equity Securities Exempt Offering Net Of Issuance Costs ProceedsFromIssuanceOfEquitySecuritiesExemptOfferingNetOfIssuanceCosts		usd
CY2023	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	NUZE	Stock Issuance Cost Accrued StockIssuanceCostAccrued		usd
CY2023	NUZE	Addition For Right Of Use Of Assets AdditionForRightOfUseOfAssets		usd
CY2023	NUZE	Addition For Lease Liability AdditionForLeaseLiability		usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross		usd
CY2022Q3	us-gaap	Goodwill Goodwill		usd
CY2023Q3	us-gaap	Goodwill Goodwill		usd
CY2022Q3	us-gaap	Goodwill Goodwill		usd
CY2023Q3	us-gaap	Goodwill Goodwill		usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue		usd
CY2023	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue		usd
CY2023	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Exercised Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExercisedNumberOfShares		shares
CY2022	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Exercised Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue		shares
CY2023	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Exercised Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExercisedNumberOfShares		shares
CY2023	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Exercised Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue		shares
CY2022Q3	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	NUZE	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2023	NUZE	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q3	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding		usd
CY2023	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Exercisable Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested		usd
CY2021Q3	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2022	NUZE	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q3	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding		usd
CY2022	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Exercisable Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested		usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39338
CY2023	dei	Entity Registrant Name EntityRegistrantName	NUZEE, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	38-3849791
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2865 Scott St. Suite 107
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Vista
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92081
CY2023	dei	City Area Code CityAreaCode	(760)
CY2023	dei	Local Phone Number LocalPhoneNumber	295-2408
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value
CY2023	dei	Trading Symbol TradingSymbol	NUZE
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	7263908	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1281736	shares
CY2023	dei	Auditor Firm AuditorFirmId	206
CY2023	dei	Auditor Name AuditorName	MaloneBailey, LLP
CY2023	dei	Auditor Location AuditorLocation	Houston, Texas
CY2023Q3	us-gaap	Cash Cash	1373101	usd
CY2022Q3	us-gaap	Cash Cash	8315053	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	586878	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	345258	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	998070	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	947995	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	418200	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	547773	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	3376249	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	10156079	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	309555	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525075	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	403258	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	642624	usd
CY2023Q3	us-gaap	Investments Investments	162259	usd
CY2022Q3	us-gaap	Investments Investments	169634	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	110000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	140000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79677	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	77962	usd
CY2023Q3	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	755194	usd
CY2022Q3	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	1030220	usd
CY2023Q3	us-gaap	Assets Assets	4440998	usd
CY2022Q3	us-gaap	Assets Assets	11711374	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1903923	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	820200	usd
CY2023Q3	us-gaap	Loans Payable Current LoansPayableCurrent	4753	usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	7947	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	216128	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	388325	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	26048	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	24518	usd
CY2023Q3	us-gaap	Deferred Income Current DeferredIncomeCurrent	379795	usd
CY2022Q3	us-gaap	Deferred Income Current DeferredIncomeCurrent	319707	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	25756	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	39241	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2556403	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1599938	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162301	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	267786	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	29622	usd
CY2022Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	4745	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	47937	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	66484	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	210238	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	368637	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2766641	usd
CY2022Q3	us-gaap	Liabilities Liabilities	1968575	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	748644	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	748644	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	676229	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	676229	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	8	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	7	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	74925843	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	74281418	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73371987	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64622520	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	120493	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	83894	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1674357	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9742799	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4440998	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11711374	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3348831	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3109162	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	3340013	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3219575	usd
CY2023	us-gaap	Gross Profit GrossProfit	8818	usd
CY2022	us-gaap	Gross Profit GrossProfit	-110413	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	8880435	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	11292105	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-8871617	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-11402518	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	365766	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	191631	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-7375	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-5791	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	251656	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	574710	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	15415	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-6324	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8749467	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11797712	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.95
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.95
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-21.32
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-21.32
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	732421	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	732421	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	553322	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	553322	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8749467	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11797712	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	36599	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-113929	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	36599	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-113929	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8712868	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11911641	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9742799	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	40000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	135870	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	288030	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	180526	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	36599	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8749467	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1674357	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	12212447	usd
CY2022	NUZE	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	1702596	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	95256	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1649736	usd
CY2022	NUZE	Stock Issued During Period Value Other One StockIssuedDuringPeriodValueOtherOne	2520868	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	426844	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2899338	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12600	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	134755	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-113929	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11797712	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9742799	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8749467	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11797712	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	220653	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	379474	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	239366	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	302334	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-41108	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-12618	usd
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	288030	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2899338	usd
CY2023	us-gaap	Restricted Stock Expense RestrictedStockExpense	180526	usd
CY2022	us-gaap	Restricted Stock Expense RestrictedStockExpense	134755	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	135870	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	117015	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	34351	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-7375	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-5791	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	675134	usd
CY2022	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	368783	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	358635	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-175629	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	50075	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	364867	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-186653	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	65485	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1715	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1860	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1053158	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-67844	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	60088	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	143885	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-277682	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-300847	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-18547	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	682	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6926279	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7462121	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16241	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	191765	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	413069	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16241	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-604834	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	7939	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	43622	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	95256	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1702596	usd
CY2022	NUZE	Proceeds From Issuance Of Equity Securities Exempt Offering Net Of Issuance Costs ProceedsFromIssuanceOfEquitySecuritiesExemptOfferingNetOfIssuanceCosts	1649736	usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	2656460	usd
CY2023	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	28092	usd
CY2022	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	24260	usd
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	368783	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12600	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-36031	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5679983	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	36599	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-113929	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6941952	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2500901	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8315053	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10815954	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1373101	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8315053	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	4944	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	9811	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	800	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	800	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	426844	usd
CY2022	NUZE	Stock Issuance Cost Accrued StockIssuanceCostAccrued	135592	usd
CY2023	NUZE	Forgiveness Of Stock Issuance Costs ForgivenessOfStockIssuanceCosts	40000	usd
CY2023	NUZE	Deferred Stock Offering Cost Accrued Rou Assets And Liabilities Added During Period DeferredStockOfferingCostAccruedRouAssetsAndLiabilitiesAddedDuringPeriod	57080	usd
CY2022	NUZE	Deferred Stock Offering Cost Accrued Rou Assets And Liabilities Added During Period DeferredStockOfferingCostAccruedRouAssetsAndLiabilitiesAddedDuringPeriod	558371	usd
CY2022Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	ratio from 1-for-10 to 1-for-50
CY2022Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-35 reverse stock split of our common stock (the “Reverse Stock Split”).
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	248856	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	265941	shares
CY2023Q3	us-gaap	Cash Cash	1373101	usd
CY2023Q3	NUZE	Working Capital WorkingCapital	819846	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zhV8leFyuPFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zRgwC3ufaFl5">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing these consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zeHNRxCxbuyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zeoEZ6HwcUkg">Concentration of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash with high quality banking institutions. From time to time, the Company may or may not maintain cash balances at certain institutions in excess of the Federal Deposit Insurance Corporation limit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	58636	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	6862	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	642624	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	239366	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	403258	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	656111	usd
CY2023	NUZE	Operating Lease Lease Liability Amortization Expense OperatingLeaseLeaseLiabilityAmortizationExpense	277682	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	378429	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	216128	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162301	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	378429	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	326362	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	67310	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	393672	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	15243	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	378429	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	216128	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162301	usd
CY2023Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M6D
CY2023Q3	us-gaap	Lessee Finance Lease Discount Rate LesseeFinanceLeaseDiscountRate	0.1275	pure
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4944	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	27594	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	27594	usd
CY2023Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1546	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	26048	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	26048	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	349890	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4385	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	28092	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	214108	usd
CY2023Q3	NUZE	Sub Lease Liability Payments Due Next Twelve Months SubLeaseLiabilityPaymentsDueNextTwelveMonths	97377	usd
CY2023Q3	NUZE	Minimum Lease Payments To Be Received Sublease MinimumLeasePaymentsToBeReceivedSublease	97377	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	36599	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-113929	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-7375	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-5791	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	273965	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	192316	usd
CY2023	us-gaap	Other Expenses OtherExpenses	251656	usd
CY2022	us-gaap	Other Expenses OtherExpenses	574710	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	418200	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	547773	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	418200	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	547773	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	998070	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	947995	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	982626	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	887632	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15444	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	60363	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	998070	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	947995	usd
CY2023	us-gaap	Depreciation Depreciation	190653	usd
CY2022	us-gaap	Depreciation Depreciation	333196	usd
CY2023	NUZE	Property And Equipment Description PropertyAndEquipmentDescription	Expenditures associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment that exceed $1,000 are capitalized.
CY2023Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1895859	usd
CY2022Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1930898	usd
CY2023Q3	us-gaap	Public Utilities Property Plant And Equipment Vehicles PublicUtilitiesPropertyPlantAndEquipmentVehicles	73980	usd
CY2022Q3	us-gaap	Public Utilities Property Plant And Equipment Vehicles PublicUtilitiesPropertyPlantAndEquipmentVehicles	73008	usd
CY2022Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	62122	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1660284	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1540953	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	309555	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525075	usd
CY2023	NUZE	Purchase Of Deposit Equipment PurchaseOfDepositEquipment	0	usd
CY2022	NUZE	Purchase Of Deposit Equipment PurchaseOfDepositEquipment	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	531412	usd
CY2023	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50% likelihood
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3348831	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3109162	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	309555	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525075	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	531412	usd
CY2022	NUZE	Non Cash Impairment Charges For The Dripkit Tradename NonCashImpairmentChargesForTheDripkitTradename	80555	usd
CY2022	NUZE	Non Cash Impairment Charges For Acquried Customer NonCashImpairmentChargesForAcquriedCustomer	63167	usd
CY2022Q3	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	140000	usd
CY2023Q3	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	110000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	110000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	30000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	30000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	46278	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	30000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	30000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	30000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	20000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	110000	usd
CY2022Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	25279	shares
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	70
CY2022Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1649736	usd
CY2022	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardTerms	P10Y
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	113650	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	149.88
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1207	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.15
CY2023	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted	P9Y10M17D
CY2023	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	3343	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	145.41
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	19849	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	105.27
CY2023	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited	P4Y2M1D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	96458	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	150.39
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M2D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	72429	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	173.24
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y11M26D
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	400	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	16086	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	128965	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	165.55
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	452206	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5285	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	46.9
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	400	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	31.50
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	4114	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	679.70
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	16086	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	109.20
CY2022	NUZE	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercisable In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisableInPeriodWeightedAverageExercisePrice	158.24
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	113650	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	149.88
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1207	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	63641	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	150.65
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y6M
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	82057	shares
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	175.70
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5285	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	29.40
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	16086	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	108.15
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	21247	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	213.85
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	50009	shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	154.24
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.30
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	19849	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	104.41
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	12131	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	307.72
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	24029	shares
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	81.33
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	152398	shares
CY2022Q3	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1	158.24
CY2022	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm	P3Y8M12D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	152398	shares
CY2023Q3	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1	158.24
CY2023	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm	P2Y7M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Other ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther	152398	shares
CY2023	NUZE	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercisable In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisableInPeriodWeightedAverageExercisePrice	158.24
CY2023	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTermExercisable	P2Y7M24D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	138103	shares
CY2021Q3	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1	174.30
CY2021	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm	P4Y6M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	25279	shares
CY2022	NUZE	Share Based Compensation Arrangements By Share Based Payment Award Non Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice	70.00
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	10984	shares
CY2022	NUZE	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice	157.85
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	152398	shares
CY2022Q3	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1	158.24
CY2022	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm	P3Y8M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Other ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther	152398	shares
CY2022	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTermExercisable	P3Y8M12D
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1702596	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	NUZE	Deferred Income Tax Assets Valuation Allowance Percentage DeferredIncomeTaxAssetsValuationAllowancePercentage	1	pure
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	45340996	usd
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	37663761	usd
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The earliest tax year which remains open to examination is 2020.
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12413540	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10263914	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5944806	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5775567	usd
CY2023Q3	NUZE	Deferred Tax Assets Fixed Assets And Intangible Assets DeferredTaxAssetsFixedAssetsAndIntangibleAssets	21071	usd
CY2022Q3	NUZE	Deferred Tax Assets Fixed Assets And Intangible Assets DeferredTaxAssetsFixedAssetsAndIntangibleAssets	168498	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18379417	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16207979	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18379417	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16207979	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
nuze-20230930_pre.xml	Edgar Link	unprocessable
0001493152-24-002501-index-headers.html	Edgar Link	pending
0001493152-24-002501-index.html	Edgar Link	pending
0001493152-24-002501.txt	Edgar Link	pending
0001493152-24-002501-xbrl.zip	Edgar Link	pending
ex10-20.htm	Edgar Link	pending
ex10-20_001.jpg	Edgar Link	pending
ex10-20_002.jpg	Edgar Link	pending
ex10-20_003.jpg	Edgar Link	pending
ex10-20_004.jpg	Edgar Link	pending
ex10-20_005.jpg	Edgar Link	pending
ex10-20_006.jpg	Edgar Link	pending
ex10-20_007.jpg	Edgar Link	pending
ex10-20_008.jpg	Edgar Link	pending
ex10-20_009.jpg	Edgar Link	pending
ex10-20_010.jpg	Edgar Link	pending
ex10-20_011.jpg	Edgar Link	pending
ex10-20_012.jpg	Edgar Link	pending
ex10-20_013.jpg	Edgar Link	pending
ex10-20_014.jpg	Edgar Link	pending
ex10-20_015.jpg	Edgar Link	pending
ex10-20_016.jpg	Edgar Link	pending
ex10-20_017.jpg	Edgar Link	pending
ex10-20_018.jpg	Edgar Link	pending
ex10-20_019.jpg	Edgar Link	pending
ex10-20_020.jpg	Edgar Link	pending
ex10-20_021.jpg	Edgar Link	pending
ex10-20_022.jpg	Edgar Link	pending
ex10-21.htm	Edgar Link	pending
ex10-21_001.jpg	Edgar Link	pending
ex10-21_002.jpg	Edgar Link	pending
ex10-21_003.jpg	Edgar Link	pending
ex10-21_004.jpg	Edgar Link	pending
ex10-21_005.jpg	Edgar Link	pending
ex10-21_006.jpg	Edgar Link	pending
ex10-21_007.jpg	Edgar Link	pending
ex10-21_008.jpg	Edgar Link	pending
ex10-21_009.jpg	Edgar Link	pending
ex10-21_010.jpg	Edgar Link	pending
ex10-21_011.jpg	Edgar Link	pending
ex10-21_012.jpg	Edgar Link	pending
ex10-21_013.jpg	Edgar Link	pending
ex10-21_014.jpg	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nuze-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
nuze-20230930_cal.xml	Edgar Link	unprocessable
nuze-20230930_def.xml	Edgar Link	unprocessable
nuze-20230930_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMG
Stock $img

2024 Q1 Form 10-K Financial Statement

#000149315224002501 Filed on January 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMG Stock $img

2024 Q1 Form 10-K Financial Statement

#000149315224002501 Filed on January 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMG
Stock $img